Asset Dedication LLC’s Ligand Pharmaceuticals LGND Stock Holding History

Asset Dedication LLC’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.44K	Buy	+11	New	+$3.25K	﹤0.01%	964

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

St. Denis J. Villere & Co New Orleans, Louisiana $775M AUM 13.27% 1-Year Est. Return

Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Asset Dedication LLC's LGND Position: Q3 2026 in Review

Asset Dedication LLC opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2026: 11 shares worth $3.44K. The stake represents ﹤0.01% of the portfolio and ranks #964 among its holdings.

158 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Asset Dedication LLC held 11 shares of Ligand Pharmaceuticals worth $3.44K as of Q3 2026.
Ligand Pharmaceuticals was a new Asset Dedication LLC position in Q3 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Asset Dedication LLC's portfolio in Q3 2026, its #964 holding.
158 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Asset Dedication LLC's 13F filing for Q3 2026, filed 3 Nov 2026.